Mission Statement, Vision, & Core Values (2024) of Allogene Therapeutics, Inc. (ALLO)

Mission Statement, Vision, & Core Values (2024) of Allogene Therapeutics, Inc. (ALLO)

US | Healthcare | Biotechnology | NASDAQ

Allogene Therapeutics, Inc. (ALLO) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Allogene Therapeutics, Inc. (ALLO)

General Summary of Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic CAR T cell therapies for cancer treatment. Founded in 2018, the company is headquartered in South San Francisco, California.

Company Detail Information
Founding Year 2018
Headquarters South San Francisco, California
Stock Ticker ALLO

Key product pipeline includes:

  • ALLO-501: CD19 CAR T cell therapy
  • ALLO-715: Multiple myeloma CAR T cell therapy
  • ALLO-316: Solid tumor CAR T cell therapy

Financial Performance

Financial Metric 2023 Value
Total Revenue $39.4 million
Net Loss $337.5 million
Cash and Investments $596.3 million

Industry Leadership

Allogene Therapeutics is a pioneer in allogeneic CAR T cell therapy development, focusing on innovative off-the-shelf cell therapies that could potentially transform cancer treatment approaches.

Clinical Trial Stage Number of Trials
Phase 1/2 Trials 4 active trials
Solid Tumor Trials 2 ongoing trials



Mission Statement of Allogene Therapeutics, Inc. (ALLO)

Mission Statement of Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics, Inc. focuses on developing innovative allogeneic CAR T cell therapies for cancer treatment.

Core Mission Components

Component Specific Details Key Metrics
Research Focus Allogeneic CAR T cell therapies 7 clinical-stage product candidates
Target Indication Hematologic and solid tumor cancers Multiple phase 1/2 clinical trials
Innovation Approach Gene editing technologies $386.4 million cash and investments (Q3 2023)

Research Pipeline Strategic Objectives

  • Develop off-the-shelf CAR T cell therapies
  • Utilize TALEN gene editing platform
  • Target multiple cancer indications

Clinical Development Metrics

As of Q3 2023:

  • Market Capitalization: $483.16 million
  • Cash Position: $386.4 million
  • Research and Development Expenses: $214.1 million (2022)

Key Product Candidates

Product Indication Clinical Stage
ALLO-501 Large B-cell Lymphoma Phase 1/2
ALLO-715 Multiple Myeloma Phase 1/2



Vision Statement of Allogene Therapeutics, Inc. (ALLO)

Vision Statement of Allogene Therapeutics, Inc. (ALLO)

Pioneering Allogeneic CAR T Cell Therapy Landscape

Allogene Therapeutics aims to revolutionize cancer treatment through off-the-shelf allogeneic CAR T cell therapies. As of Q4 2023, the company's vision focuses on developing transformative cell therapies targeting multiple cancer types.

Strategic Vision Components

Innovative Cell Therapy Platform

Key platform technologies include:

  • ALPHA™ (Allogeneic Platform)
  • SLICE™ Gene Editing Technology
  • Universal CAR T Cell Manufacturing Strategy

Clinical Development Priorities

Program Cancer Type Clinical Stage
ALLO-501 Relapsed/Refractory Large B-Cell Lymphoma Phase 1 Clinical Trial
ALLO-715 Multiple Myeloma Phase 1 Clinical Trial
Research & Development Investment

R&D Expenditure in 2023: $294.7 million

Technological Differentiation

Unique technological approaches include:

  • Off-the-shelf allogeneic CAR T cell therapies
  • Proprietary gene-editing techniques
  • Scalable manufacturing processes

Financial Performance Indicators

Metric 2023 Value
Cash and Investments $687.4 million
Net Loss $336.2 million



Core Values of Allogene Therapeutics, Inc. (ALLO)

Core Values of Allogene Therapeutics, Inc. (ALLO) in 2024

Innovation and Scientific Excellence

Allogene Therapeutics demonstrates commitment to innovation through substantial R&D investments.

R&D Expenses (2023) $323.4 million
Number of Active Clinical Trials 7 ongoing trials
Patent Applications 23 active patent families

Patient-Centric Approach

Focused on developing advanced cell therapies for cancer treatment.

  • Specialized in allogeneic CAR T cell therapies
  • Targeting multiple cancer indications
  • Developing off-the-shelf cell therapy solutions

Collaborative Research Ecosystem

Strategic partnerships drive scientific advancement.

Research Collaborations 4 active institutional partnerships
Academic Partnerships 2 major research institutions

Ethical and Transparent Operations

Commitment to regulatory compliance and scientific integrity.

  • Full FDA compliance
  • Regular internal and external audits
  • Transparent clinical trial reporting

Financial Sustainability

Strategic financial management supporting research initiatives.

Cash and Investments (Q4 2023) $493.2 million
Annual Revenue (2023) $12.6 million
Net Loss (2023) $386.7 million

DCF model

Allogene Therapeutics, Inc. (ALLO) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.